These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. Burks AW; Wood RA; Jones SM; Sicherer SH; Fleischer DM; Scurlock AM; Vickery BP; Liu AH; Henning AK; Lindblad R; Dawson P; Plaut M; Sampson HA; J Allergy Clin Immunol; 2015 May; 135(5):1240-8.e1-3. PubMed ID: 25656999 [TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358 [TBL] [Abstract][Full Text] [Related]
4. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness. Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313 [TBL] [Abstract][Full Text] [Related]
5. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization. Kim EH; Yang L; Ye P; Guo R; Li Q; Kulis MD; Burks AW J Allergy Clin Immunol; 2019 Nov; 144(5):1320-1326.e1. PubMed ID: 31493887 [TBL] [Abstract][Full Text] [Related]
6. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children. Kim EH; Keet CA; Virkud YV; Chin S; Ye P; Penumarti A; Smeekens J; Guo R; Yue X; Li Q; Kosorok MR; Kulis MD; Burks AW J Allergy Clin Immunol; 2023 Jun; 151(6):1558-1565.e6. PubMed ID: 36828080 [TBL] [Abstract][Full Text] [Related]
7. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial. Kim EH; Bird JA; Keet CA; Virkud YV; Herlihy L; Ye P; Smeekens JM; Guo R; Yue X; Penumarti A; Qaqish B; Li Q; Kulis MD; Burks AW J Allergy Clin Immunol; 2024 Jan; 153(1):173-181.e10. PubMed ID: 37815782 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW; Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of allergen-specific immunotherapy for peanut allergy: a meta-analysis of randomized controlled trials. Sun J; Hui X; Ying W; Liu D; Wang X Allergy Asthma Proc; 2014; 35(2):171-7. PubMed ID: 24717795 [TBL] [Abstract][Full Text] [Related]
14. Peanut gastrointestinal delivery oral immunotherapy in adolescents: Results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study). Fauquert JL; Michaud E; Pereira B; Bernard L; Gourdon-Dubois N; Rouzaire PO; Rochette E; Merlin E; Evrard B; Clin Exp Allergy; 2018 Jul; 48(7):862-874. PubMed ID: 29665158 [TBL] [Abstract][Full Text] [Related]
15. Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy. Kulis M; Saba K; Kim EH; Bird JA; Kamilaris N; Vickery BP; Staats H; Burks AW J Allergy Clin Immunol; 2012 Apr; 129(4):1159-62. PubMed ID: 22236732 [TBL] [Abstract][Full Text] [Related]
16. Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial. Michaud E; Evrard B; Pereira B; Rochette E; Bernard L; Rouzaire PO; Gourdon-Dubois N; Merlin E; Fauquert JL Trials; 2015 Apr; 16():197. PubMed ID: 25925398 [TBL] [Abstract][Full Text] [Related]
17. Food-specific sublingual immunotherapy is well tolerated and safe in healthy dogs: a blind, randomized, placebo-controlled study. Maina E; Pelst M; Hesta M; Cox E BMC Vet Res; 2017 Jan; 13(1):25. PubMed ID: 28100257 [TBL] [Abstract][Full Text] [Related]
18. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results. Fleischer DM; Shreffler WG; Campbell DE; Green TD; Anvari S; Assa'ad A; Bégin P; Beyer K; Bird JA; Brown-Whitehorn T; Byrne A; Chan ES; Cheema A; Chinthrajah S; Chong HJ; Davis CM; Ford LS; Gagnon R; Greenhawt M; Hourihane JO; Jones SM; Kim EH; Lange L; Lanser BJ; Leonard S; Mahler V; Maronna A; Nowak-Wegrzyn A; Oriel RC; O'Sullivan M; Petroni D; Pongracic JA; Prescott SL; Schneider LC; Smith P; Staab D; Sussman G; Wood R; Yang WH; Lambert R; Peillon A; Bois T; Sampson HA J Allergy Clin Immunol; 2020 Oct; 146(4):863-874. PubMed ID: 32659313 [TBL] [Abstract][Full Text] [Related]